Dr. Sonpavde on the Potential for Immunotherapy in Penile Cancer

Guru Sonpavde, MD
Published: Tuesday, Jan 02, 2018



Guru Sonpavde, MD, director of Bladder Cancer at the Dana-Farber Cancer Institute, discusses the potential for immunotherapy in penile cancer.

There is promise for PD-1 checkpoint inhibitors, as well as CTLA-4 plus PD-L1 combination strategies in the treatment of patients with penile cancer, says Sonpavde.

Sonpavde says that he expects activity with immunotherapy regimens because PD-L1 is overexpressed in over 50% of tumors, and about 50% of patients have disease derived from HPV.
 


Guru Sonpavde, MD, director of Bladder Cancer at the Dana-Farber Cancer Institute, discusses the potential for immunotherapy in penile cancer.

There is promise for PD-1 checkpoint inhibitors, as well as CTLA-4 plus PD-L1 combination strategies in the treatment of patients with penile cancer, says Sonpavde.

Sonpavde says that he expects activity with immunotherapy regimens because PD-L1 is overexpressed in over 50% of tumors, and about 50% of patients have disease derived from HPV.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™: Choosing Therapies for Patients with EGFR-mutant Lung Cancers: More Options... More Decisions... Better OutcomesApr 27, 20182.0
Community Practice Connections™: 21st Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and MyelomaApr 27, 20182.0
Publication Bottom Border
Border Publication
x